Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

BofA moved to No Rating on Bluebird Bio (BLUE) after the company announced it has entered a definitive merger agreement under which Carlyle and ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.

By Sneha S K (Reuters) -Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle Group and SK Capital ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...